KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Depreciation & Amortization (CF) (2018 - 2025)

Esperion Therapeutics' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $21000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 22.22% year-over-year to $21000.0; the TTM value through Dec 2025 reached $100000.0, up 58.73%, while the annual FY2025 figure was $100000.0, 58.73% up from the prior year.
  • Depreciation & Amortization (CF) reached $21000.0 in Q4 2025 per ESPR's latest filing, down from $26000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $153000.0 in Q1 2021 to a low of $6000.0 in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $75736.8, with a median of $51000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 93.48% in 2023, then soared 350.0% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $153000.0 in 2021, then crashed by 39.87% to $92000.0 in 2022, then plummeted by 93.48% to $6000.0 in 2023, then skyrocketed by 350.0% to $27000.0 in 2024, then dropped by 22.22% to $21000.0 in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Depreciation & Amortization (CF) are $21000.0 (Q4 2025), $26000.0 (Q3 2025), and $27000.0 (Q2 2025).